- Home
- PEBK vs ACTU Comparison
PEBK vs ACTU Comparison
Compare PEBK & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEBK
- ACTU
- Stock Information
- Founded
- PEBK 1912
- ACTU 2015
- Country
- PEBK United States
- ACTU United States
- Employees
- PEBK N/A
- ACTU N/A
- Industry
- PEBK Major Banks
- ACTU
- Sector
- PEBK Finance
- ACTU
- Exchange
- PEBK Nasdaq
- ACTU NYSE
- Market Cap
- PEBK 148.4M
- ACTU 135.0M
- IPO Year
- PEBK N/A
- ACTU 2024
- Fundamental
- Price
- PEBK $27.84
- ACTU $7.47
- Analyst Decision
- PEBK
- ACTU Strong Buy
- Analyst Count
- PEBK 0
- ACTU 1
- Target Price
- PEBK N/A
- ACTU $20.00
- AVG Volume (30 Days)
- PEBK 6.9K
- ACTU 85.1K
- Earning Date
- PEBK 07-21-2025
- ACTU 05-15-2025
- Dividend Yield
- PEBK 3.39%
- ACTU N/A
- EPS Growth
- PEBK 4.04
- ACTU N/A
- EPS
- PEBK 3.05
- ACTU N/A
- Revenue
- PEBK $83,033,000.00
- ACTU N/A
- Revenue This Year
- PEBK N/A
- ACTU N/A
- Revenue Next Year
- PEBK N/A
- ACTU N/A
- P/E Ratio
- PEBK $9.08
- ACTU N/A
- Revenue Growth
- PEBK 7.01
- ACTU N/A
- 52 Week Low
- PEBK $23.74
- ACTU $5.51
- 52 Week High
- PEBK $33.31
- ACTU $11.99
- Technical
- Relative Strength Index (RSI)
- PEBK 47.99
- ACTU N/A
- Support Level
- PEBK $27.41
- ACTU N/A
- Resistance Level
- PEBK $28.25
- ACTU N/A
- Average True Range (ATR)
- PEBK 0.58
- ACTU 0.00
- MACD
- PEBK -0.05
- ACTU 0.00
- Stochastic Oscillator
- PEBK 34.67
- ACTU 0.00
About PEBK Peoples Bancorp of North Carolina Inc.
Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.